Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 19

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach

Rasool, Muhammad Fawad, Khalil, Feras, Läer, Stephanie·2016·Drug Metabolism and Disposition
DOI 10.1124/dmd.115.068858
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/dmd.115.068858

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 44

  1. Aiba, 2005, Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers, Biol Pharm Bull, 28, 114, 10.1248/bpb.28.114 · DOI
  2. Benet, 2011, BDDCS applied to over 900 drugs, AAPS J, 13, 519, 10.1208/s12248-011-9290-9 · DOI
  3. Berezhkovskiy, 2004, Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination, J Pharm Sci, 93, 1628, 10.1002/jps.20073 · DOI · Paper page
  4. Berkowitz, 1963, Malabsorption as a complication of congestive heart failure, Am J Cardiol, 11, 43, 10.1016/0002-9149(63)90029-8 · DOI
  5. Birkett, 1989, Racemates or enantiomers: regulatory approaches, Clin Exp Pharmacol Physiol, 16, 479, 10.1111/j.1440-1681.1989.tb01591.x · DOI
  6. Caron, 1999, Structure-Lipophilicity relationships of neutral and protonated β-blockers, part I, intra- and intermolecular effects in isotropic solvent systems, Helv Chim Acta, 82, 1211, 10.1002/(SICI)1522-2675(19990804)82:8<1211::AID-HLCA1211>3.0.CO;2-K · DOI
  7. Cubitt, 2011, Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model, Xenobiotica, 41, 623, 10.3109/00498254.2011.560294 · DOI
  8. De Buck, 2007, Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs, Drug Metab Dispos, 35, 1766, 10.1124/dmd.107.015644 · DOI · Paper page
  9. Fleming, 2011, Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies, Lancet, 377, 1011, 10.1016/S0140-6736(10)62226-X · DOI · Paper page
  10. Fujimaki, 1990, Assay and disposition of carvedilol enantiomers in humans and monkeys: evidence of stereoselective presystemic metabolism, J Pharm Sci, 79, 568, 10.1002/jps.2600790704 · DOI
  11. Gehr, 1999, The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency, Eur J Clin Pharmacol, 55, 269, 10.1007/s002280050628 · DOI
  12. Giessmann, 2004, CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects, Clin Pharmacol Ther, 75, 213, 10.1016/j.clpt.2003.10.004 · DOI
  13. Hsu, 2009, Heart failure in children: part I: history, etiology, and pathophysiology, Circ Heart Fail, 2, 63, 10.1161/CIRCHEARTFAILURE.108.820217 · DOI
  14. Jamei, 2009, Population-based mechanistic prediction of oral drug absorption, AAPS J, 11, 225, 10.1208/s12248-009-9099-y · DOI · Paper page
  15. Johnson, 2011, Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice, Paediatr Anaesth, 21, 291, 10.1111/j.1460-9592.2010.03323.x · DOI
  16. Kaijser, 1997, Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients, Clin Transplant, 11, 577, 10.1111/j.1399-0012.1997.tb01046.x · DOI
  17. Khalil, 2014, Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range: sotalol as a model drug, AAPS J, 16, 226, 10.1208/s12248-013-9555-6 · DOI · Paper page
  18. Läer, 2002, Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters, Am Heart J, 143, 916, 10.1067/mhj.2002.121265 · DOI
  19. Leithe, 1984, Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure, Circulation, 69, 57, 10.1161/01.CIR.69.1.57 · DOI
  20. Li, 2012, Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling, Acta Pharmacol Sin, 33, 1359, 10.1038/aps.2012.103 · DOI · Paper page
  21. Nakamura, 1994, The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure, Clin Pharmacol Ther, 56, 160, 10.1038/clpt.1994.119 · DOI
  22. Neugebauer, 1990, Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound, Eur J Clin Pharmacol, 38, S108, 10.1007/BF01409476 · DOI
  23. Neugebauer, 1991, Metabolism of carvedilol in man, Eur J Drug Metab Pharmacokinet, 16, 257, 10.1007/BF03189969 · DOI
  24. Noda, 1997, Liver volume in children measured by computed tomography, Pediatr Radiol, 27, 250, 10.1007/s002470050114 · DOI
  25. Ogawa, 2013, Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously), Clin Pharmacokinet, 52, 169, 10.1007/s40262-012-0029-2 · DOI
  26. Ogawa, 2014, Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally), Clin Pharmacokinet, 53, 1083, 10.1007/s40262-014-0189-3 · DOI
  27. Ohno, 2004, Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol, Drug Metab Dispos, 32, 235, 10.1124/dmd.32.2.235 · DOI
  28. Oldham, 1997, In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol, Drug Metab Dispos, 25, 970
  29. Rasool, 2015, A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows, Clin Pharmacokinet, 54, 943, 10.1007/s40262-015-0253-7 · DOI · Paper page
  30. Ross, 1992, Grading the severity of congestive heart failure in infants, Pediatr Cardiol, 13, 72, 10.1007/BF00798207 · DOI
  31. Salem, 2014, A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data, Clin Pharmacokinet, 53, 625, 10.1007/s40262-014-0140-7 · DOI
  32. Salem, 2013, Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions, J Clin Pharmacol, 53, 857, 10.1002/jcph.100 · DOI
  33. Sehrt, 2011, Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics, Pharmacogenomics, 12, 783, 10.2217/pgs.11.20 · DOI
  34. Sica, 2003, Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics, Congest Heart Fail, 9, 287, 10.1111/j.1527-5299.2003.02399.x · DOI
  35. Spahn, 1990, Measurement of carvedilol enantiomers in human plasma and urine using S-naproxen chloride for chiral derivatization, Arch Pharm, 323, 465, 10.1002/ardp.19903230805 · DOI
  36. Takekuma, 2012, Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes, Biol Pharm Bull, 35, 151, 10.1248/bpb.35.151 · DOI
  37. Tenero, 2000, Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure, J Clin Pharmacol, 40, 844, 10.1177/00912700022009576 · DOI
  38. Tian, 2012, Determination of the enantioselectivity of six chiral aryloxy aminopropanol drugs transport across Caco-2 cell monolayers, Acta Pharm Sin B, 2, 168, 10.1016/j.apsb.2012.02.005 · DOI
  39. Tucker, 1990, Enantiomer specific pharmacokinetics, Pharmacol Ther, 45, 309, 10.1016/0163-7258(90)90069-E · DOI
  40. Wessler, 2013, The P-glycoprotein transport system and cardiovascular drugs, J Am Coll Cardiol, 61, 2495, 10.1016/j.jacc.2013.02.058 · DOI
  41. Wilkinson, 1975, Commentary: a physiological approach to hepatic drug clearance, Clin Pharmacol Ther, 18, 377, 10.1002/cpt1975184377 · DOI · Paper page
  42. Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation, 128, 1810, 10.1161/CIR.0b013e31829e8807 · DOI · Paper page
  43. Zelis, 1975, Abnormalities in the regional circulations accompanying congestive heart failure, Prog Cardiovasc Dis, 18, 181, 10.1016/0033-0620(75)90010-9 · DOI
  44. Zhou, 1995, Stereoselective disposition of carvedilol is determined by CYP2D6, Clin Pharmacol Ther, 57, 518, 10.1016/0009-9236(95)90036-5 · DOI

Cited by

Metadata

Authors
Rasool, M. F., Khalil, F., & Läer, S.
Venue
Drug Metabolism and Disposition
Publisher
Elsevier BV
Published
2016-07
Volume
44
Issue
7
Pages
1103-1115
ISSN
0090-9556
DOI
10.1124/dmd.115.068858
Cited by
19
References
3
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.